Last reviewed · How we verify
EVOREL® CONTI
EVOREL CONTI is a transdermal patch that delivers continuous estradiol and norethisterone to provide hormone replacement therapy for menopausal symptoms.
EVOREL CONTI is a transdermal patch that delivers continuous estradiol and norethisterone to provide hormone replacement therapy for menopausal symptoms. Used for Menopausal vasomotor symptoms (hot flushes, night sweats), Menopausal urogenital symptoms, Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | EVOREL® CONTI |
|---|---|
| Also known as | Evorel Conti transdermal patch 25 mcg transdermal dose |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust |
| Drug class | Hormone replacement therapy (HRT) — combined estrogen/progestin |
| Target | Estrogen receptors (ER-α, ER-β) and progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
The patch releases estradiol (a natural estrogen) and norethisterone (a synthetic progestin) through the skin in a continuous manner, bypassing first-pass hepatic metabolism. This maintains stable hormone levels to alleviate vasomotor symptoms (hot flushes, night sweats) and other menopausal symptoms while the progestin component protects the endometrium in women with an intact uterus.
Approved indications
- Menopausal vasomotor symptoms (hot flushes, night sweats)
- Menopausal urogenital symptoms
- Osteoporosis prevention in postmenopausal women
Common side effects
- Breast tenderness
- Headache
- Nausea
- Skin irritation at patch site
- Vaginal bleeding/spotting
Key clinical trials
- Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy (PHASE4)
- The Effects of Tualang Honey on Postmenopausal Women (PHASE2, PHASE3)
- A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVOREL® CONTI CI brief — competitive landscape report
- EVOREL® CONTI updates RSS · CI watch RSS
- Royal Brompton & Harefield NHS Foundation Trust portfolio CI